Navigation Links
Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes
Date:4/26/2010

TAMPA, Fla., April 26 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic biopharmaceutical company, announced today that Zirgan™ (ganciclovir ophthalmic gel) 0.15% is now commercially available.  Zirgan™, which was approved by the U.S. Food and Drug Administration in September 2009, is a topical ophthalmic antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers).  

(Logo: http://www.newscom.com/cgi-bin/prnh/20100426/FL92821LOGO )

"Sirion began shipping Zirgan™ to drug distributors and retail chains today," said Barry Butler, of Sirion Therapeutics, Inc. "Healthcare professionals can begin prescribing Zirgan™ and pharmacies should be able to fill the prescription immediately or within 24 hours if the pharmacy has to order it from their drug distributor.  We have received an overwhelming number of inquiries regarding Zirgan™ and its availability and are proud to be providing eye care professionals with the first innovation in ocular antiviral therapy in the US in over 30 years."

Zirgan™ is a topical ophthalmic gel formulation that appears clear and colorless and is supplied in a 5 gram polycoated aluminum tube with a white polyethylene tip and cap and protective band (NDC 42826-605-50).  For additional product information, please visit our website at www.siriontherapeutics.com or call our customer support number (1-866-4SIRION).  For sample requests please call 1-888-387-0853.

About Herpetic Keratitis

Herpetic Keratitis is the number one infectious cause of corneal blindness in the U.S.  Herpes simplex virus infections are very common, with nearly 60% of the US population showing evidence of infection by age five. Approximately 1% of infected patients develop ocular outbreaks, with 20,000 primary cases of ocular herpes diagnosed in the US each year. After the primary infection, ocular HSV typically becomes latent until triggers such as stress, UV radiation, and hormonal changes reactivate the virus and cause recurrent outbreaks. Those recurrences account for an additional 28,000 cases per year in the US. The risk of blindness increases with the number and severity of recurrences, making prompt treatment imperative to limit corneal scarring and other more serious ocular complications caused by herpetic ulcers.

About Zirgan™ (ganciclovir ophthalmic gel) 0.15%

Zirgan™ (ganciclovir ophthalmic gel) 0.15% is indicated for topical ophthalmic use as a treatment for acute herpetic keratitis (dendritic corneal ulcers).  Zirgan™ is an innovative topical antiviral therapy designed to specifically target herpes virus infected cells.  Zirgan™ has been a leading treatment for corneal ulcers, under the brand name Virgan®, in Europe for more than 10 years.  

The recommended dosing for Zirgan™ is one drop five times per day until the ulcer heals, and then one drop three times per day for seven days.  Zirgan™ is indicated for topical ophthalmic use only.  Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with Zirgan™. The most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).

About Sirion Therapeutics, Inc.

Sirion Therapeutics, Inc. is a privately held biopharmaceutical company located in Tampa, Florida.   For more information, please visit www.siriontherapeutics.com.


'/>"/>
SOURCE Sirion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sirion Therapeutics Announces Positive Phase III Results for Difluprednate
2. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
3. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
4. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... DUBLIN, Ohio , Feb. 4, 2016 ... Pricing Program, or those already participating in the program, ... Guidance, often referred to as the , Mega-Guidance , ... the final guidance is published in September 2016. ... 340B Product and Service Marketing , summarizes the Mega-Guidance,s ...
(Date:2/4/2016)... Feb. 4, 2016 Worldwide Radiology Oncology ... growth as next generation systems provide a way ... for cancer surgery. New systems pinpoint the delivery ... has been such a problem previously, limiting the ... robots take cancer surgery far beyond what has ...
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... ... the addition of micro-needling services in their Napa Valley office. The technique utilizes ... Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a ...
(Date:2/5/2016)... ... ... After years as an active staff surgeon and having served as the ... Carman transitioned to chief of the Division of Plastic Surgery at what is now ... and began a second three-year term in January of 2016. , The original selection ...
(Date:2/5/2016)... ... February 05, 2016 , ... In the fourth quarter of ... at the La Valencia Hotel in San Diego, California to discuss changes in ... year’s most outstanding franchise, walking away with the coveted David Wright Award of ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... to search for and donate to Give To Cure’s campaign that is crowdfunding clinical ... lets users make and share payments through a smart device. In 2015 alone, Venmo ...
(Date:2/5/2016)... New York, New York (PRWEB) , ... February 05, 2016 , ... ... (APDA) announced the election of Patrick McDermott as Chairman of the National Board of ... welcome Pat as Chairman of the Board,” stated Leslie A. Chambers , APDA ...
Breaking Medicine News(10 mins):